A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity
Authors
Keywords
Epidermal growth factor receptor, Somatic amino acid mutation, Drug resistance and sensitivity, Kinase inhibitor, Non-small cell lung cancer
Journal
AMINO ACIDS
Volume 46, Issue 7, Pages 1635-1648
Publisher
Springer Nature
Online
2014-03-21
DOI
10.1007/s00726-014-1716-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
- (2013) Kadoaki Ohashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors
- (2013) Yi-Hui Peng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides
- (2012) Caterina Carmi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
- (2012) S Yoshikawa et al. ONCOGENE
- Use of QM/MM scheme to reproduce macromolecule–small molecule noncovalent binding energy
- (2012) Xinchun Guo et al. Computational and Theoretical Chemistry
- Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
- (2011) R. Rosell et al. CLINICAL CANCER RESEARCH
- Accurate assessment of the strain energy in a protein-bound drug using QM/MM X-ray refinement and converged quantum chemistry
- (2011) Zheng Fu et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Characterization of PDZ domain–peptide interactions using an integrated protocol of QM/MM, PB/SA, and CFEA analyses
- (2011) Feifei Tian et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
- (2011) Fenlai Tan et al. LUNG CANCER
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Why OppA protein can bind sequence-independent peptides? A combination of QM/MM, PB/SA, and structure-based QSAR analyses
- (2010) Feifei Tian et al. AMINO ACIDS
- Mixed Quantum Mechanics/Molecular Mechanics Scoring Function To Predict Protein−Ligand Binding Affinity
- (2010) Seth A. Hayik et al. Journal of Chemical Theory and Computation
- QM/MM based 3D QSAR models for potent B-Raf inhibitors
- (2010) Jae Yoon Chung et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
- (2010) Robert C. Doebele et al. LUNG CANCER
- Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase-Targeted Agents in Non-Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor
- (2010) K. Takezawa et al. MOLECULAR CANCER THERAPEUTICS
- QM/MM Study of Epitope Peptides Binding to HLA-A*0201: The Roles of Anchor Residues and Water
- (2009) Yuanchao Li et al. Chemical Biology & Drug Design
- Mechanisms of tumor resistance to EGFR-targeted therapies
- (2009) Elizabeth A Hopper-Borge et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Insights into the Structural Basis of N2 and O6 Substituted Guanine Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors: Prediction of the Binding Modes and Potency of the inhibitors by Docking and ONIOM Calculations
- (2009) Jans H. Alzate-Morales et al. Journal of Chemical Information and Modeling
- QM/MM Calculations in Drug Discovery: A Useful Method for Studying Binding Phenomena?
- (2009) M. Paul Gleeson et al. Journal of Chemical Information and Modeling
- QM/MM As a Tool in Fragment Based Drug Discovery. A Cross-Docking, Rescoring Study of Kinase Inhibitors
- (2009) M. Paul Gleeson et al. Journal of Chemical Information and Modeling
- Fluorine Bonding — How Does It Work In Protein−Ligand Interactions?
- (2009) Peng Zhou et al. Journal of Chemical Information and Modeling
- Halogen BondingA Novel Interaction for Rational Drug Design?
- (2009) Yunxiang Lu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations
- (2008) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- 2D depiction of nonbonding interactions for protein complexes
- (2008) Peng Zhou et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started